Piper Sandler Calls AtriCure Inc. (ATRC) an 'Underappreciated Story'
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $50.00 price target on AtriCure Inc. (NASDAQ: ATRC).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
